Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2015

View Archived Issues

Cimzia begins phase III program for psoriasis

NIH signs agreement with Vtesse to develop treatments for Niemann-Pick disease type C

Bio Blast reports preliminary data from trial of Cabaletta in oculopharyngeal muscular dystrophy

Protalix reports interim data from phase I/II trial of PRX-102 for Fabry disease

Results from first phase III trial of Sativex for cancer pain

H&P Labs forms in-licensing agreement with Harvard University for Ebola treatment

Isarna files to begin clinical studies of ISTH-0036 for ophthalmic diseases

New TOPK-specific inhibitor induces tumor regression in xenograft model of lung cancer

Sangamo BioSciences in-licenses mRNA delivery technology

Biocept and Insight Genetics to advance NSCLC diagnostics

Horizon Discovery acquires Haplogen Genomics

Bone marrow hypoxia parallels leukemia progression

Novel hyperforin derivatives disclosed by Indena

Institute of Radiation Medicine divulges novel tyrosine kinase inhibitors for cancer

Karyopharm Therapeutics patents novel Exp1 inhibitors

MyoKardia prepares and tests new drugs for hypertrophic cardiomyopathy

Researchers in China present novel PARP-1 inhibitors

Helsinn Group obtains rights to license Monofer in the U.S.

FDA approves Duopa to treat motor fluctuations in advanced Parkinson's disease

GlyT1 inhibitor improves cognition and sociability in mouse model of ASD

China approves Epidaza for peripheral T-cell lymphoma

Phase III NSCLC trial stopped early after Opdivo shows superior overall survival to docetaxel

Biogen Idec to acquire Convergence Pharmaceuticals

Cornerstone initiates phase I study of CPI-613 for metastatic colorectal cancer

FDA awards orphan drug status to Sparsentan for focal segmental glomerulosclerosis

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026